%PDF-1.5
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2020-03-16T18:07:05+08:00
2020-03-16T18:07:05+08:00
2020-03-16T18:07:05+08:00
Adobe InDesign CC 2017 (Windows)
uuid:9046f030-2388-4489-88a9-af57c0b07125
xmp.did:f079f6ee-09ad-5b49-ba04-e8476e6cc10c
xmp.id:9712eabd-e484-ff4e-9b20-73abe7cf6e7c
proof:pdf
xmp.iid:a85731b2-5660-a349-b2d7-79a129733662
xmp.did:61a7be35-6261-c840-94c5-11058c44ef1c
xmp.did:f079f6ee-09ad-5b49-ba04-e8476e6cc10c
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2020-03-16T18:07:05+08:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>>
endobj
19 0 obj
<>stream
BT
/CS0 cs 0 0 0 1 scn
/Perceptual ri
/GS0 gs
/T1_0 1 Tf
12 0 0 12 285.6378 18.7502 Tm
(\226 2 \226)Tj
0.037 Tc 0.071 Tw -19.079 63.041 Td
[(quarantine)12.1 ( )0.5 (measures)12 ( )0.5 (has)12.1 ( )0.5 (limited)12 ( )0.5 (personnel)12 ( )0.5 (movements)12 ( )0.5 (between)12 ( )0.5 (the)12 ( )0.5 (Group\222s)12 ( )0.5 (manufacturing)12 ( )]TJ
0.043 Tc 0.07 Tw 0 -1.333 TD
[(sites)12.4 ( and)12.4 ( offices,)12.4 ( and)12.4 ( this)12.4 ( has)12.4 ( also)12.4 ( reduced)12.4 ( the)12.4 ( number)12.4 ( of)12.5 ( non-urgent)12.5 ( health)12.4 ( care)12.4 ( services)18.1 ( )]TJ
0.029 Tc 0.079 Tw T*
[(including)4 ( )0.5 (surgery)4 ( )0.5 (and)4 ( )0.5 (antenatal)4 ( )0.5 (checkup,)4 ( )0.5 (which)4 ( )0.5 (in)4 ( )0.5 (turn)4 ( )0.5 (slows)4 ( )0.5 (the)4 ( )0.5 (demand)4.1 ( )0.5 (for)4 ( )0.6 (the)4.1 ( )0.5 (respective)4.1 ( )]TJ
0.025 Tc 0.06 Tw 0 -1.333 TD
(drugs. Meanwhile, the demand for chronic disease medications remains int\
act. In light of the )Tj
0.065 Tw 0 -1.333 TD
(epidemic situation, the Group\222s financial position remains solid and \
will continue to monitor )Tj
0.055 Tc 0.07 Tw T*
[(the)12.3 ( further)12.3 ( development)12.3 ( of)12.3 ( the)12.3 ( epidemic)12.3 ( and)12.3 ( market)12.3 ( conditions)12.3 ( as)12.3 ( well)12.3 ( as)12.3 ( the)12.3 ( risks)12.3 ( and)30 ( )]TJ
0.025 Tc 0 Tw 0 -1.333 TD
(uncertainties faced by the Group as a result.)Tj
0.041 Tw 0 -2.667 TD
(As of today, there have been no confirmed cases of COVID-19 within the G\
roup\222s workforce )Tj
0.079 Tc 0.07 Tw 0 -1.333 TD
[(in)12.2 ( mainland)12.2 ( China,)12.2 ( Hong)12.2 ( Kong)12.2 ( and)12.2 ( Taiwan.)12.2 ( The)12.2 ( Group)12.2 ( will)12.3 ( continue)12.3 ( to)12.2 ( implement)54 ( )]TJ
0.054 Tc 0 -1.333 TD
[(comprehensive)12.9 ( and)12.9 ( stringent)12.9 ( prevention)12.8 ( and)12.8 ( control)12.8 ( measures)12.9 ( strictly)12.9 ( to)12.9 ( ensure)12.9 ( that)12.8 ( the)29 ( )]TJ
0.025 Tc 0 Tw T*
(Group\222s employees can work in a safe and healthy environment.)Tj
0.076 Tw 0 -2.667 TD
(The Company is still in the process of finalising the results for the ye\
ar ended 31 December )Tj
0.034 Tc 0.074 Tw 0 -1.333 TD
[(2)9 (0)9 (1)9 (9)9 (.)9 ( )0.5 (The)9 ( )0.5 (information)9 ( )0.5 (contained)9.1 ( )0.5 (in)9 ( )0.5 (this)9 ( )0.5 (announcement)9 ( )0.5 (is)9 ( )0.5 (only)9 ( )0.5 (a)9 ( )0.5 (preliminary)9 ( )0.5 (assessment)9 ( )0.5 (by)9 ( )]TJ
0.049 Tc 0.07 Tw 0 -1.333 TD
[(the)12.7 ( Board)12.7 ( based)12.7 ( on)12.7 ( information)12.7 ( currently)12.7 ( available)12.7 ( including)12.6 ( the)12.7 ( unaudited)12.7 ( consolidated)24 ( )]TJ
0.039 Tc 0 -1.333 TD
[(management)12.6 ( accounts)12.6 ( of)12.6 ( the)12.6 ( Group)12.6 ( for)12.6 ( the)12.6 ( year)12.6 ( ended)12.6 ( 3)12.6 (1)12.6 ( December)12.6 ( 2)12.6 (0)12.6 (1)12.6 (9)12.5 (,)12.6 ( which)12.5 ( have)12.6 ( not)14.1 ( )]TJ
0.025 Tc 0 Tw T*
(been confirmed, reviewed or audited by the auditors of the Company.)Tj
0.033 Tc 0.075 Tw 0 -2.667 TD
[(Further)8 ( )0.5 (information)8 ( )0.5 (and)8 ( )0.5 (other)8 ( )0.5 (details)8 ( )0.5 (of)8 ( )0.5 (the)8 ( )0.5 (Group\222s)8 ( )0.5 (financial)8 ( )0.5 (results)8 ( )0.5 (for)8 ( )0.5 (the)8 ( )0.5 (year)8 ( )0.5 (ended)8 ( )0.5 (3)8 (1)8 ( )]TJ
0.048 Tc 0.07 Tw 0 -1.333 TD
[(December)12.1 ( 2)12.2 (0)12 (1)12.1 (9)12.1 ( will)12.1 ( be)12.1 ( disclosed)12.1 ( in)12.1 ( the)12.1 ( forthcoming)12.1 ( annual)12.1 ( results)12.1 ( announcement)12.1 ( of)12.1 ( the)23.1 ( )]TJ
0.025 Tc 0 Tw 0 -1.333 TD
(Company, which is expected to be published on 26 March 2020.)Tj
/T1_1 1 Tf
0.01 Tw 0 -2.667 TD
(Shareholders and potential investors are advised to exercise cautions wh\
en dealing in the )Tj
0 Tw 0 -1.333 TD
(shares of the Company.)Tj
/T1_0 1 Tf
24.311 -2.667 Td
(By order of the Board of)Tj
/T1_1 1 Tf
-3.719 -1.333 Td
(Lee\222s Pharmaceutical Holdings Limited)Tj
5.992 -1.333 Td
(Lee Siu Fong)Tj
/T1_2 1 Tf
-0.025 Tw 0.828 -1.333 Td
(Chairman)Tj
/T1_0 1 Tf
0 Tw -27.412 -2.667 Td
(Hong Kong, 16 March 2020)Tj
/T1_2 1 Tf
0.033 Tc 0.075 Tw 0 -2.667 TD
[(As)8.1 ( )0.5 (at)8 ( )0.5 (the)8 ( )0.6 (date)8 ( )0.5 (of)8 ( )0.5 (this)8 ( )0.5 (announcement,)8 ( )0.5 (Ms.)8 ( )0.5 (Lee)8 ( )0.5 (Siu)8 ( )0.5 (Fong)8 ( )0.5 (\(Chairman\),)8 ( )0.5 (Ms.)8 ( )0.5 (Leelalertsuphakun)8 ( )]TJ
0.025 Tc 0.072 Tw 0 -1.333 TD
(Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simo\
n Miles Ball is a )Tj
0.06 Tw T*
(non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam \
Yat Cheong and )Tj
0 Tw 0 -1.333 TD
(Dr. Tsim Wah Keung, Karl are independent non-executive directors of the \
Company.)Tj
ET
endstream
endobj
13 0 obj
<>
endobj
17 0 obj
<>
endobj
14 0 obj
<>
endobj
24 0 obj
<>
endobj
25 0 obj
<>stream
H\j0Fl/WiҤ\pIjhd8yta
g5.7.+}]kjbYoϻ=7cQ2yCQ7/Su7(ROfu?lqrZΎ9ѷfޜ͕sît{1}U2elZKMW3Q m?
endstream
endobj
26 0 obj
<>stream
H{XSOsorʉ=9
/TPm7T"$@!@B Inp+6;'O|6}j̮a'hg<{~}?x7GFȖ4#4,EwN.)Bo''|mgO^0Q
soTT&$,tk^
ڰSvՔZ+V2ӕdLNe4*Wjd,f*Q2UwQjt2fS/H1
P3RF˲LF)F2sدUtFh2d̶`&0Ҝt&_ޱr"M6-1\{T)WraT́|BH(9HeBb=;YZ&_/!;Yͤ>l6[cK15l56(Kc\_,bWxz^'owg_|#|?[w ߊGΏw
BL[;Kg̛;Ggj
!/)_5;fŀ2L\쉛0P>wbx'u "yj nNE΄PYI*QSc-`hc8<* SKq6Z¨H
\-ro@Efͅ9a]h».aUz4sh^|L^Mbс͓XBf'XUV,#*4WȒ)CTY*-Vљ]7(}i}4Y1j
NM4WƼE5j:ZhX˭ 9)yTI]#-?PuUĭm͝ǟgmk_ڊi!DP욯D>v::t%OkK8Y q7_zR(r !cߐn%SE}-d^WvJI^}-:2mNuCϳBNOqqbͲrb]Guyp7}pov4,*-rG?QXrvl>RN,RhԄ{sœpG
tv@~V1s/_l?*;߶_}Fz#sYN+54).6.Mh59vf줖l]䝜u;XĶ.ؿ I2tg?ð2 $D4GӹQt(mh <>3 ):I
b4#w0L^i@&=Ey[ˠiұvUxC_/y7URkO6[^o,ݔެ*M7Xg///,7gU58vyK+KkJjjV'Ћc竎U)*.zgWWؤ!y
jmzD64f(9T[:sSucbX_e6 8]0v
xˎ,zۜALJ-h;ZLJ}.ԥVusyzp;ř[K9z8[Q)[ɝ>g'`>2沍4rm0b<xu_KLNsY$$zZG1EVo2Y]B u}5G$_P{]8gU96/(suW}ĉ^e{qċ$`a։hx.K_nK}͵<'oz
@&Hd
8i+*ʍY4 $L>Uϴ;:{>W&x
Q@>MQ3:젽4-cM>cg;\կ`}r`3DC
X[+8ujg8xe[Fb;c +ڕ<$zZOkm8Y@j GڏSeG5uga(V{^X#vNuFSH+." A!,wjwQVuZ=mg}Ώ=g}˹wn~~t/ ueu'l~ls䮛^./B/m܈V$mc5wݔ"&xQl]җk͎GUTK؉ޯikɒ#jyW"Po(Ee(S9ƴ`^WOGpOo-0T
^oF+/\y od!$u^["cN/ڛ W:x*9=-=A'_zBcV7R%*oʐܑ>2N'̏=m6L,+hQ(HJNHuуUKJ]axVTZxCK` y11uqgY\Q3\d0s;Ly
UZl-ǫx [iV.
Ek{A&IR;j@58 ,2ʻw#-`HI3Ze& [51;!F+чs>6'lo<#Y1O=~sYXl>z![65qV*K}#q0%ܶEAOqLupNNx.(KLd4qZ#|l8|p0ko4%ۧ o˝,+7O,xjZ z|!<9}5U5YJ6Y@+R-U-m`kyѥm uoU `?@,w7 ,72NWUa)^3e HO̟xQ#R1!hNGXփ8!7ZyLV[b1%-u^`:ǖ YD.Ug%(,a'ӡuWk5Z뾿=GŜXN˶OKNtp9q .l'`).fKJTby
EޞG7p56DfUz *U(?E.h f Ya-4Y\'ZoT_. i2d7&a| -ۛخ`OCbc(yEZYPć:4~acPS)7ii?s&&hB? x9NoncO[g_fTyy y'_lOEl8#Lr+)-S9XA="ma`DbVX26ۨKG$[֡M1.!M;=ߐKQJ*AxyR1չ.#<sѝu%PrcxA\/t3rD⢲q|lWDpщ,)QIc}t2MFhInNˣ[-5vɤeXMAc(MO ӧ/0 8^$lЌptQf*ۅlT>grdr1otmw+Kɫ`oAKOݾ{pg!ޙa7-Q)Dݰw3>~]]ĒMD*6ٶ+#@UmuޅNp/D{~{l֫]YT8d9?5a+@j\vÚT<"e!Zy#HT/2W
җrijh(.Ӡ((13!P:k`ZgbUb*cQ)RTP! WnWawؓeefgWv=Kce!(Ā9,K#+`K+I__{ޕw/?Q姙FC]
&!.BOGbъ߾tS]+CxKܼX!)-zP4\BN7
|Cp)m<|c܅cѶNچ;{^QD87NS,Ob
KʃZr}hszAZ1V."zIP)D eNy=9T6xR?7l,Dѩ1l
.5nb֡Q
]ņgspBd,F!3Sjro{s.;]wA;
u,.C{jL^,ns7xg (p^^̳|so$f;hL>;R-]?>{